Also as single agents, MRK-003 and DAPT were tested in primary NSCLC cultures and shown to be effective in decreasing growth potential and cell survival in both Numb-Low and Notch1-mutant cells [78], while 50 μM DAPT treatment for two weeks in high-Notch CD44+CD24− CSCs results in reduced cell growth and decreased colony-forming ability [93]. This evidence concerns the gene CD24 and non-small cell lung carcinoma.